Hikma and Celltrion sign exclusive licensing agreements for six biosimilars across MENA

Territory is described as MENA regionally; no African country is named in the trade coverage available to this run, so the African nexus is regional only.


Coverage: The Meridian legal market record (editorial).

Territory is described as MENA regionally; no African country is named in the trade coverage available to this run, so the African nexus is regional only.

Record ID TX-AFR-2025-0012
Record type Commercial IP transaction
Transaction type Patent licence, Exclusive licence, In-licensing
IP rights patent, know-how, regulatory data
Status Signed
Qualifying date 2025-10-06
Sector Life sciences · Pharmaceuticals – biosimilars
African markets Multi-jurisdictional
Licensed territory MENA region.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, single · 1 source(s)
Last verified 2026-10-25

Parties

  • Hikma Pharmaceuticals PLC (United Kingdom): licensee
  • Celltrion Inc. (South Korea): licensor

Key terms

  • Interest: exclusive licence; Exclusivity: exclusive; Territorial scope: MENA region

Sources

  1. Hikma and Celltrion deepen alliance to boost biosimilar access in MENA, PharmaTimes, 2025-10-06

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.